Boceprevir triple therapy of HCV genotype 1 (G1) infection in German real-life: comparable high SVR rates up to 87% in treatment-naïve and previously treated patients who achieve…
P Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, C John, P Geyer, B Weber, T Witthöft, A Herrmann, M Hoesl, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer · Zeitschrift für Gastroenterologie · 2015 · Heft 08
Bibliografische Angaben
Zusammenfassung
Background: Since 2011, triple therapy with the HCV protease inhibitor boceprevir (BOC) is widely used as standard of care for patients (pts) with chronic HCV G1 infection. The present interim analysis of the German NOVUS observational study was aimed to compare the efficacy of BOC triple therapy in previously untreated and previously treated patients in German real-world and, in particular, to compare the virologic outcome of pts who achieve an early virologic response (EVR) at treatment week (TW) 8. Methods: From April 2012 until January 2014, 536 pts with genotype 1 infection were recruited in the ongoing NOV…
